跳至主要内容
临床试验/CTRI/2009/091/000713
CTRI/2009/091/000713已完成不适用

Adherent Monitoring of Congestive Heart Failure during Therapy for Excess Fluid (ACUTE) Study

Corventis Inc1 个研究点 分布在 1 个国家目标入组 60 人开始时间: 2009年3月14日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
60
试验地点
1
主要终点
To gather data to correlate physiological signals with the patient?s fluid status and heart failure symptoms during recovery from acute heart failure decompensation.

研究概览

简要总结

This is a prospective, multi-center, non-randomized study. Patients who have been admitted to the hospital with fluid overload will be enrolled into the study and monitored with the investigational device for up to 2 weeks. The system will continuously record physiologic variables such as heart rate, fluid conductance, activity and respiration.

研究设计

研究类型
Interventional
分配方式
Not Applicable
盲法
Open Label

入排标准

年龄范围
18.00 Year(s) 至 99.00 Year(s)(—)
性别
All

入选标准

  • •Potential patients must meet all of the following criteria: 1.Is female or male, 18 years of age or older 2.Has an ejection fraction of 40% reported within 12 months of enrollment 3.Have acute decompensated heart failure and receiving treatment for fluid overload 4.Is willing to provide written informed consent and comply with study guidelines.

排除标准

  • •Patients will be excluded from the study if they meet any of the following criteria1.Has an implantable device with an active minute ventilation sensor 2.Has a known allergy or hypersensitivity to adhesives or hydrogel3.Has received the first treatment for this episode of acute heart failure decompensation more than 24 hours ago4.Is participating in another clinical study that may confound the results of this study.

结局指标

主要结局

To gather data to correlate physiological signals with the patient?s fluid status and heart failure symptoms during recovery from acute heart failure decompensation.

时间窗: Analyses in addition to the primary endpoint analysis will include:ii) Summarizing the incidence and frequency of all adverse events reported during the study. Events will be classified by the study sites into adverse events, serious adverse events (SAEs), and/or unanticipated adverse device effects (UADEs). Severity of each event will be classified as mild, moderate or severe. The relationship to the investigational device will be determined using a classification of Definite, Probable, Possible or None. The number and percent of patients experiencing each event will be presented with the number and percent of the following: SAE, UADE, moderate events, severe events, definitely related events, probably related events and possibly related events.

次要结局

未报告次要终点

研究者

发起方
Corventis Inc
申办方类型
Pharmaceutical industry-Global

研究点 (1)

Loading locations...

相似试验